Table 2.

Data Gaps That Will Be Addressed by Typhoid Vaccine Acceleration Consortium (TyVAC)–Sponsored Trials

Data Elements	Status
Safety	•Bangladesh, Malawi, Nepal trial data—presented to WHO Global Advisory Committee on Vaccine Safety, 2018 •Data collection ongoing, including special populations (HIV-infected, HIV-exposed, malnourished children)
Immunogenicity in endemic settings outside of India	•Bangladesh, Malawi, Nepal trial data—presented at the 11th International Conference on Typhoid and Other Invasive Salmonelloses, 26–28 March 2019, Hanoi, Vietnam •Studies ongoing in Burkina Faso, Malawi, and Nepal to explore immunogenicity at 9 vs 15 months; with 1 vs 2 doses of vaccine; and in HIV-exposed children
Efficacy and impact in endemic setting	•Nepal—first-year efficacy data against laboratory-confirmed infection presented at the 11th International Conference on Typhoid and Other Invasive Salmonelloses, 26–28 March 2019, Hanoi, Vietnam and in peer-reviewed literature. Trial ongoing. •Individually randomized trial ongoing in Malawi •Cluster-randomized trial followed by catch-up vaccinations ongoing in Bangladesh
Coadministration with other vaccines	•Burkina Faso: TCV with measles-rubella, yellow fever, meningitis A •Malawi: TCV with measles-rubella
Duration of protection	•Trials currently funded for 2–2.5 y of follow-up

Abbreviations: HIV, human immunodeficiency virus; TCV, typhoid conjugate vaccine; WHO, World Health Organization.